Goldman Sachs initiated coverage of LivaNova with a Buy rating and $65 price target The company is entering a period with “clear and more visible baseline growth drivers,” augmented by potential revenue and earnings upside from new product cycles and pipeline optionality, the analyst tells investors in a research note. The firm says positive earnings revisions and continued business momentum can re-rate the shares higher over the next 12-months.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIVN:
- LivaNova upgraded to Outperform from Neutral at Baird
- LivaNova Announces CHRO Hebbelinck’s Planned Departure and Benefits
- LivaNova jumps 5% to $49.15 after Baird note on CMS panel vote
- CMS vote on reimbursement could be win for LivaNova, says Baird
- CMS panel votes favorable for CVRx, says Lake Street